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Agnoprotein deletion mutantK (BKV) genome encodes the capsid proteins VP1 to VP3 and the three regulatory
proteins, large and small tumor-antigen and the agnoprotein. Agnoprotein is a phospho-protein, but
phosphorylation sites, protein kinases that mediate phosphorylation, and the biological importance of
phosphorylation for the life-cycle of BK virus remain unknown. Here, we show that protein kinase C
phosphorylates BKV agnoprotein at serine-11. Replacing serine-11 by either non-phosphorylable alanine or
phospho-mimicking aspartic acid reduced the ability of these mutants to propagate compared to wildtype
virus. Moreover, both these mutants displayed altered expression of viral proteins, which resulted from
changed transrepressive property and stability of the mutated agnoprotein. Our results indicate that BKV
propagation is controlled by phosphorylation of the agnoprotein and may suggest that speciﬁc inhibition of
protein kinases may be used as a therapeutic strategy to hamper BK virus infection.
© 2008 Elsevier Inc. All rights reserved.Introduction
Polyomaviridae are non-enveloped viruses with an icosahedral
capsid of about 40–45 nm in diameter and they contain a circular
double-strandedDNAmolecule of approximately 5000bp.Members of
this family have been identiﬁed in several organisms, including birds,
bovine, rodents, monkeys and human (Eash et al., 2006). The ﬁrst
human polyomaviruses were originally isolated in 1971 by two in-
dependent research groups. Gardner and coworkers isolated BK virus
(BKV) in the urine of a renal transplant patient with the initials B.K.,
while Padgett and colleagues characterized a virus in the brain of a
Hodgkin's lymphoma patient with initials J.C. who suffered from
progressive multifocal leukencephalopathy. The Rhesus macaques
virus SV40 was accidentally introduced into the human population via
contaminated vaccines, but recent studies reveal antibodies against
SV40 and SV40 nucleic acid sequences in individuals that had never
received such vaccines nor had contact with monkeys (reviewed in
Moens et al., 2007a,b). Therefore SV40 may also be considered as a
human virus (Moens et al., 2007a,b). All these three human viruses
have been associated with human pathologies. JCV is the etiological
agent of PML (Khalili and White, 2006), while BKV is associated with
nephropathy in renal transplant patients, hemorrhagic cystitis in boneen).
l rights reserved.marrow recipients (Hirsch, 2005; Hirsch and Steiger, 2003), and the
autoimmune disease systemic lupus erythematosus (Van Ghelue et al.,
2003). SV40 is considered to play a causative role in mesothelioma
(Pass et al., 2004). Recently, three novel human polyomaviruses have
been described. KI and WU were discovered in respiratory secretions
(Allander et al., 2007; Gaynor et al., 2007), while Merkel cell poly-
omavirus (MCV) was described as the likely causative agent of Merkel
skin cancer (Feng et al., 2008).
The JCV, BKV and SV40 genomes possess a tripartite functional
organizationwith the noncoding control region (NCCR) that separates
the early gene and late gene region. The early region encodes the
regulatory proteins large tumor-antigen (LT-ag) and small tumor-
antigen (st-ag), while the late region encodes the structural capsid
proteins VP1, VP2 and VP3 as well as the regulatory agnoprotein
(reviewed byMoens and Rekvig, 2001). For SV40, a fourth late protein,
VP4, was recently identiﬁed as a protein involved in lytic death of host
cell and release of viral progeny (Daniels et al., 2007).
The agnoprotein of JCV, BKV and SV40 has a high degree of
sequence conservation, especially in the N-terminal half of the protein
where 31 or 25 amino acids out of 37 is identical between BKV and JCV
or BKV and SV40, respectively. The agnoprotein has been shown to
reside predominantly in the cytosol and in the perinuclear region in
associationwith the outer nuclearmembrane, but aminor fraction can
also be detected in the nucleus of SV40- and JCV-infected cells (Khalili
et al., 2005). Studies in JCV and/or SV40 have suggested that
agnoprotein is involved in nuclear egress (Okada et al., 2005), gene
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(Khalili et al., 2005). The function of BKV agnoprotein in the viral life
cycle has not been investigated so far.
Phosphorylation is a common post-translational modiﬁcation of
cellular proteins and is performed by protein kinases which transfer
phosphates to serine, threonine and tyrosine residues. Phosphoryla-
tion of a target protein may modify its subcellular localization,
stability, activity, and/or contact with interaction partners (Whit-
marsh and Davis, 2000). The human genome encodes more than 500
different protein kinases, which differ in their substrate speciﬁcity,
subcellular localization, regulation and expression. Among the best
studied serine–threonine kinases are protein kinases A (PKA), C (PKC)
and D (PKD). The PKC family consists of several isoforms which are
classiﬁed into three major subfamilies: the classical PKC (α, β and γ),
novel PKC (δ, ɛ, η, and θ) and atypical PKC (ξ and ι) (Webb et al., 2000).
The PKD family comprises PKD1, PKD2 and PKD3 (Rozengurt et al.,
2005), while PKA exists as a tetramer composed of two regulatory and
two catalytic subunits. Different isoforms of these regulatory and
catalytic subunits occur in the cell and they can assemble in different
combinations, generating different types of PKA with different
properties (Skalhegg and Tasken, 2000; Tasken and Aandahl, 2004).
The different protein kinases are activated by different stimuli,
resulting in a ﬁne-tuned mechanism allowing a speciﬁc substrate to
be phosphorylated as a consequence of a particular environmental
change (Ubersax and Ferrell, 2007).
The agnoprotein of all well-known primate polyomaviruses has
been found to be phosphorylated in vivo (Khalili et al., 2005). A recent
study revealed that Ser-7, Ser-11 and Thr-21 are phospho-acceptor
sites in JCV agnoprotein. Mutation of these sites into non-phosphor-
ylable alanine resulted in disturbed viral propagation (Sariyer et al.,
2006). The Ser-7 and -11 residues are conserved in SV40 and BKV,
while Thr-21 is conserved in BKV, but is replaced by Ser in SV40.
Whether these sites are phosphorylated in SV40 or BKV and which
kinases are involved in mediating these phosphorylations remain to
be established. Moreover, the role of phosphorylation of agnoprotein
in viral propagation of BKV and SV40 has not been elucidated.
The aim of this study was to identify the sites and protein kinases
that mediate phosphorylation of BKV agnoprotein, and to scrutinize
the biological implications of this modiﬁcation. In this study, we
show that agnoprotein of BKV can be phosphorylated at Ser-11 by
PKA, and also at additional sites by PKC and PKD in vitro. Furthermore,
we demonstrate that PKC can mediate phosphorylation of agno-
protein at Ser-11 in vivo. We provide evidence that phosphoryla-
tion of agnoprotein at Ser-11 ﬂuctuated during viral propagation
indicating an important role in the viral life cycle. Indeed, mutation of
Ser-11 residue resulted in changed viral propagation with differences
in late gene expression, compared to wildtype BKV and an agno-
deﬁcient BKV variant. Moreover, we show that agnoprotein and
agnoprotein with mutation at Ser-11 residue differ in their transre-
pression ability of late viral promoter and also in their stability, which
might partially explain the changed gene expression among the BKV
variants.
Results
BKV agnoprotein can be phosphorylated by PKA, PKC and PKD in vitro
In order to determine putative phospho-acceptor sites in BKV
agnoprotein, we ﬁrst performed a computer-aided motif search ana-
lysis of the protein. The analysis predicted Ser-7, Ser-11, Thr-21, Ser-52,
Ser-62 and Ser-66 as putative phospho-acceptor sites (Blom et al.,
1999). An amino acid sequences alignment of BKV, JCV and SV40
revealed that Ser-7, Ser-11, and Ser-62 are conserved, while Thr-21 in
BK and JC is replaced by serine in SV40. In order to determine which
sites of agnoprotein could be phosphorylated in vitro, we puriﬁed
bacterial expressed GST-agno and GST-agno variants where one orseveral of the conserved phospho-acceptor sites were mutated into
the non-phosphorylable alanine. The GST-tag was enzymatically
removed and the samples were analyzed on SDS PAGE followed by
Coomassie staining (Fig. 1A and results not shown). Agnoprotein of
all variants were successfully puriﬁed (~7 kDa fragment), but also
remaining fusion protein (~38 kDa fragment) is detected in all
samples.
PKA has previously been suggested to be involved in phosphor-
ylation-regulated subcellular localization of JCV agnoprotein (Okada
et al., 2001), and we therefore investigated the ability of PKA to
phosphorylate agnoprotein or agnoproteinwhere Ser-11 was mutated
into the non-phosphorylable alanine (S11A) in vitro. Our results
revealed that PKA clearly phosphorylated wildtype agnoprotein
devoid of the GST moiety, while agnoproteinS11A was not phos-
phorylated (Fig. 1B, upper panel). The amounts of agnoprotein used in
the kinase assaywere run on SDS PAGE in order to evaluate the protein
level. As shown in Fig. 1B (lower panel) the levels of agnoprotein used
in the assay are comparable, conﬁrming that the lack of autoradio-
graphy bands for agnoproteinS11A is because of the mutation in the
phospho-acceptor site for PKA and not the absence of protein. These
results imply that Ser-11 is the only phospho-acceptor site for PKA
in vitro.
PKCwas recently shown to phosphorylate JCV agnoprotein (Sariyer
et al., 2006), and this prompted us to test whether this kinase also
could phosphorylate agnoprotein of BKV. Wildtype or mutated BKV
agnoprotein where Ser-7, Ser-11, Thr-21 or Ser-62 was replaced by the
non-phosphorylable alanine were used in an in vitro kinase assay,
and the phosphorylated proteins were separated on SDS PAGE and
either visualized by autoradiography (Fig. 1C, upper panel) or by
immunoblot with antibodies against agnoprotein in order to compare
the amount of proteins used in the assay (Fig. 1C, lower panel). PKC
clearly mediated phosphorylation of agnoprotein (compare lane 1 and
2, upper panel). Moreover, PKC phosphorylated agnoprotein and
agnoproteinS62A approximately equally, which indicates that Ser-62
is not an in vitro phospho-acceptor site for PKC (compare lane 2 and 6,
upper panel). Substitution of Thr-21 into Ala reduced PKC-mediated
phosphorylation, while S7A and S11A mutations strongly or almost
completely abrogated PKC-mediated phosphorylation, indicating
that all three sites may be phospho-acceptor sites for PKC in vitro,
although with different afﬁnity. We therefore extended these studies
and tested whether double and triple mutants of agnoprotein could
be phosphorylated by PKC. The stoichiometry of the phosphorylated
double mutant S11A/T21A and S7A/S11A was slightly less compared
to the single mutant agnoproteinS11A, while PKC-induced phosphor-
ylation was completely abolished in the S11A/T21A/S7A mutant
(Fig. 1D). The levels of agnoprotein used in the assays were similar
as determined by western blot, conﬁrming that the lack of phos-
phorylation is not due to less protein (Fig. 1C and D, lower panels).
These results indicate that Ser-7, Ser-11 and Thr-21 can be phosphory-
lated by PKC in vitro.
PKD has an unique substrate speciﬁcity, with a consensus sequence
LXRXXT⁎/S⁎, where T⁎/S⁎ denotes the target threonine and serine for
phosphorylation, respectively (Nishikawa et al., 1997; Hutti et al.,
2004; Doppler et al., 2005). Interestingly, agnoprotein Ser-11 is con-
tained within the PKD consensus motif LSRRPS⁎. Therefore we
monitored by in vitro kinase assay whether agnoprotein forms a
PKD substrate. The phosphorylation pattern of single mutants of
agnoprotein indicated that the phospho-acceptor sites for PKD are
Ser-7, Ser-11 and Thr-21, but not Ser-62 (Fig. 1E, upper panel). The
amount of proteins used in all the assays was comparable (Fig. 1E,
lower panel), again conﬁrming that the lack of phosphorylation was
due to the mutation rather than the absence of protein in the samples.
Mutation of the three phospho-acceptor sites into alanine completely
abolished PKD-mediated phosphorylation of agnoprotein (results not
shown). These results show that Ser-7, Ser-11 and Thr-21 can be
phosphorylated by PKD in vitro.
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kinases in vitro, andmutation of this site had themost pronounced effect
on the phospho-agnoprotein levels, we generated afﬁnity-puriﬁed
phospho-Ser-11 speciﬁc antibodies. The speciﬁcity of the antibody was
checked on immunoblot containing invitrophosphorylated agnoprotein
or agnoproteinS11A. As seen in Fig. 2A the phospho-Ser-11-speciﬁc
antibodyspeciﬁcally recognized the invitrophosphorylated agnoproteinFig. 2. The phospho-speciﬁc antibody speciﬁcally recognizes agnoprotein phosphory-
lated at Ser-11. (A) Puriﬁed agnoprotein or agnoprotein with the mutation S11A were
incubated in the presence or absence of PKC. An immunoblot was performed using
phospho-Ser-11 speciﬁc antibodies (upper panel). To verify equal loading and blotting of
the samples, the membrane was stripped and re-incubated with anti-agno antibodies
(lower panel). The results are representative for at least three independent experiments.
(B) Puriﬁed agnoprotein was used in a cold in vitro kinase assay with active PKA, PKC or
PKD. An immunoblot was performed with phospho-Ser-11 speciﬁc antibodies (upper
panel). To verify equal loading and blotting of the samples, the membrane was stripped
and re-incubated with anti-agno antibodies (lower panel).(lane 2), but not agnoproteinS11A (lane 4), nor unphosphorylated
agnoprotein variants (lane 1 and 3). The lower panel shows that the
amount of agnoprotein used in the experiment was comparable for all
samples. This result clearly demonstrates that the antibody against
phospho-Ser-11 agnoprotein speciﬁcally recognizes agnoprotein phos-
phorylated at Ser-11. Finally, the PKA-, PKC- and PKD-phosphorylated or
non-phosphorylated agnoprotein were separated on SDS PAGE and
immunoblotted with phospho-Ser-11 antibodies (Fig. 2B, upper panel).
The loadingwas controlled by stripping themembrane prior to addition
of antibodies against agnoprotein (Fig. 2B, lower panel). By use of this
phospho-speciﬁc antibody we conﬁrmed the PKA-, PKC- and PKD-
mediated phosphorylation of agnoprotein at Ser-11, althoughphosphor-
ylation by PKAwas only marginal compared to PKC and PKD (Fig. 2B).Fig. 1. PKA, PKC and PKD phosphorylate BKV agnoprotein in vitro. (A) Puriﬁed agno-
protein or agnoprotein single mutants in putative phosphorylation sites (Serine-7,
Serine-11, Threonine-21, and Serine-62) were separated on SDS PAGE and stained with
Coomassie blue. The molecular mass marker (in kDa) is shown in the left lane.
(B) Bacterial expressed agnoprotein or agnoprotein where Ser-11 is mutated into
alaninewere puriﬁed and used in in vitro kinase assaywith active PKA in the presence of
32P-γ-ATP. Lane 1 represents in vitro kinase of puriﬁed agnoprotein in the absence of PKA
The in vitro phosphorylated proteins were separated by SDS PAGE and visualized by
autoradiography. The lower panel shows Coomassie blue staining of the puriﬁed
agnoprotein variants used in the kinase assay. (C) Bacterial expressed agnoprotein or
agnoprotein single mutants in putative phosphorylation sites (serine-11, threonine-21,
serine 7, and serine 62) were used in in vitro kinase assaywith active PKC in the presence
of 32P-γ-ATP. Lane 1 represents in vitro kinase of puriﬁed agnoprotein in the absence of
PKC. The in vitro phosphorylated proteins were separated by SDS PAGE and visualized by
autoradiography. The lower panel shows immunoblot with anti-agno antibodies
visualizing the amount proteins used in the in vitro kinase assay. (D) Bacterial expressed
agnoprotein, agnoproteinS11A, agnoproteinS11A/T21A, agnoproteinS7A/S11A and agno-
proteinS7A/S11A/T21Awere used in in vitro kinase assaywith active PKC in the presence
of 32P-γ-ATP. Lane 1 represents in vitro kinase of puriﬁed agnoprotein in the absence of
PKC. The in vitro phosphorylated proteinswere separated on SDS PAGE and visualized by
autoradiography. The lower panel shows immunoblot with anti-agno antibodies of the
amount proteins used in the in vitro kinase assay. (E) Bacterial expressed agnoprotein or
agnoprotein single mutants in putative phosphorylation sites (Serine-7, Serine-11,
Threonine-21, and Serine-62) were used in in vitro kinase assay with active PKD in the
presence of 32P-γ-ATP. Lane 1 represents in vitro kinase of puriﬁed agnoprotein in the
absence of PKD. The in vitro phosphorylated proteins were separated on SDS PAGE and
visualized by autoradiography. The lower panel shows immunoblot with anti-agno
antibodies of the amount proteins used in the in vitro kinase assay.
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agnoprotein can be phosphorylated by PKA, PKC and PKD, while PKC
andPKDcanadditionally phosphorylate agnoproteinat Ser-7 andThr-21.
PKC α and PKD are able to phosphorylate agnoprotein at Ser-11 in
HEK293 and Vero cells
Our in vitro kinase results indicate that PKA, PKC and PKD are able
to phosphorylate agnoprotein at serine 11. Therefore, we examinedwhether extracellular stimuli which activate these kinasesmay trigger
phosphorylation of agnoprotein at Ser-11 in vivo. Thereto, we trans-
fected HEK293 and Vero cells with expression plasmid for agnoprotein
and exposed the cells to the following stimuli: 12-O-tetradecanoyl-
phorbol-13-acetate (TPA); mimics diacylglycerol-mediated signaling
pathways resulting in activation of among others classical and novel
PKCs and PKD (Brose et al., 2004), vanadate (induces oxidative stress,
and activates among others also PKD (Rozengurt et al., 2005), epi-
dermal growth factor (EGF) (activates among others atypical PKCs
Fig. 4. Phospho-Serine-11 phosphorylation levels ﬂuctuate during viral propagation. (A)Vero cells were transfected with BKV Dunlop DNA (left panel) and HUV-EC-C cells were
infected with BKV Dunlop at MOI=0.4 (right panel). Total cell extracts were harvested in a time-dependent manner and phospho-serine-11 agnoprotein levels were monitored by
immunoblot with phospho-Ser-11 speciﬁc antibodies. The expression of agnoprotein was evaluated antibodies against agnoprotein, and the loading was controlled by use of
antibodies against endogenous cellular CREB. The results are representative for three independent experiments. (B) The phospho-CREB expressionwas determined in the extracts of
Vero cells presented in (A). The ratio phospho-CREB versus CREB was calculated and is presented graphically.
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which enhances intracellular cAMP levels and PKA activity (Walsh et
al., 1968). The cell lysates were separated on SDS PAGE and an
immunoblot was performed using phospho-Ser-11 speciﬁc antibodies
(Fig. 3A, upper panel). Equal loading was veriﬁed by the use of
antibodies against agnoprotein (Fig. 3A, lower panel) The results
showed that stimulation with TPA and vanadate, but not EGF nor
forskolin, provoked phosphorylation of agnoprotein at Ser-11 in
HEK293 (Fig. 3A upper panel). Stimulation of Vero cells gave similar
results, except that in this cell line forskolin and EGF also weakly, but
reproducibly induced increased phosphorylation of agnoprotein at
Ser-11. These data suggest that only protein kinases activated by TPA
and vanadate can readily mediate phosphorylation of agnoprotein at
Ser-11 in both cell lines.
To further explore the involvement of PKA, PKC and PKD in
mediating phosphorylation of agnoprotein, we co-transfected HEK293
and Vero cells with expression plasmids for agnoprotein and
constitutive active variants of classical PKCα, novel PKC ε, atypicalFig. 3. Activationof thePKCandPKDpathways inducesphosphorylationof agnoprotein at Ser-11. (A
starved HEK293 (left panel) and Vero cells (right panel) were vehicle treated or incubated for 30
agnoprotein levels were determined bywestern blot analysis using phospho-speciﬁc antibodies th
stripped and re-incubatedwith antibodies against agnoprotein. The results are representative for th
determinedbydensitometry. The ratioof phosphorylatedagnoprotein: non-phosporylatedagnopro
set as 1, and the fold inductionof phosphorylationwas calculated related to this and is presented gra
ofpRcCMV-Agnoand2µgemptyvector (pEFneo), constitutiveactive (ca) PKCα-pEFneo, caPKCε-pE
were harvested andwhole cell extractwere used in immunoblotwith phospho-Ser-11 antibodies a
independent experiments. The relativephosphorylationof agnoprotein compared to loading level a
wells disheswith 2 µg of pRcCMV-Agno. Serum-starvedHEK293 andVero cellswere left untreated
100 nM TPA or 75 µM sodium pervanadate. Phospho-agnoprotein levels were determined by
agnoprotein. Inorder toverifyequal loading, themembranewas strippedandre-incubatedwithant
The relative phosphorylation of agnoprotein compared to loading level and vehicle treated cells
transfection the cellswere exposed to vehicle (DMSO), Gö6983 (1 µM) orGF109203X for 1h. The ce
Ser-11 speciﬁc antibodies. To verify equal loading and blotting of the samples, themembranewas st
two independent experiments. The relative phosphorylation of agnoprotein compared to loadingPKCζ, PKD1 or PKA. Of the tested kinases, PKCα and PKD were most
efﬁcient in mediating phosphorylation of agnoprotein at Ser-11 in
both cell lines. In contrast to PKCα and PKD, the presence of
constitutive variants of PKA, PKCε and PKCζ did not result in
augmented Ser-11 phosphorylation in both cell lines (Fig. 3B).
Our results demonstrate that certain isoforms of PKC and PKD can
mediate phosphorylation of agnoprotein at Ser-11 in vivo. However,
even though TPA and vanadate are well-known activators of PKC and
PKD, they may in addition also activate other signaling pathways
(Brose et al., 2004; Fantus and Tsiani, 1998). Therefore, we wanted to
conﬁrm the contribution of these kinases in phosphorylation of
agnoprotein and assayed phospho-Ser-11 agnoprotein levels in
extracts of TPA- or vanadate-stimulated HEK293 and Vero cells in
the absence or presence of the inhibitors Gö6976 (inhibits PKC α, β
and PKD) or Gö6983 (inhibits PKCα, β, γ, δ or ζ). Treatment of HEK293
or Vero cells with Gö6983 prior to stimulation with TPA or vanadate
resulted in strongly reduced phosphorylation of agnoprotein at Ser-11
compared to cells treated with TPA or vanadate alone (compare lane 4)HEK293andVero cellswere transfected in6wells disheswith2µgofpRcCMV-Agno. Serum-
min with 100 nM TPA, 75 µM sodium pervanadate, 10 ng/ml EGF, or 10 µM Fsk. Phospho-
at recognize phospho-Ser-11 agnoprotein. In order to verify equal loading, themembranewas
ree independent experiments. The intensity of the protein bands in the presented ﬁgurewas
teinwas calculated. The relative ratio in thepresenceof vehicle oremptyvectorwasarbitrarily
phically below theblot. (B)HEK293andVero cellswere transfected in6wells disheswith2µg
Fneo, caPKCζ-pcDNA3,caPKD1-pcDNA3orpSR-Cαexpressionvector. The serum-starvedcells
nd the loadingwas veriﬁedwith anti-agno-antibodies. The results are representative for three
ndvehicle treated cellswere evaluatedas inA. (C)HEK293andVero cellswere transfected in6
or incubatedGö6976 (1 µM) orGö6983 (1 µM) for 1 h or/and subsequently exposed 30min to
western blot analysis using phospho-speciﬁc antibodies that recognize phospho-serine-11
ibodies against agnoprotein. The results are representative for three independentexperiments.
were evaluated as in A. (D) Vero cells were transfected with BKV (Dunlop) DNA. 47 h post
llswere subsequently harvested and the cell lysateswereused for immunoblotwithphospho-
ripped and re-challengedwith antibodies against agnoprotein. The result is representative for
level and vehicle treated cells were evaluated as in A.
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levels of total agnoprotein were similar in the samples, indicating that
the decreased phosphorylation is not due to reduced protein levels
(Fig. 3C, lower panel). The reduced phosphorylation of Ser-11 in
presence of Gö6983 indicate that PKC α, β, γ, δ or ζ are involved inFig. 5.Mutation of Ser-11 inﬂuences the ability of viral propagation. (A)Vero cells were tran
or BKV-Δagno. The cell extracts were harvested 2 days post transfection (dpt), and viral
position of the unspeciﬁc band that was also observed in untransfected cells is indica
Densitometry of the protein bands was performed on the presented blot. The expression
protein was arbitrary set as 1, and the levels of mutant proteins were related according to
BKV wt or mutants were collected 4 d.p.t and used for infection of HUV-EC-C cells. The H
antibodies. The nucleus was stained with DRAQ5. The results are representative for three in
pictures (total of 5–600 cells), and the standard deviation was calculated. The differences
signiﬁcant (pb0.005) except between BKVagnoS11D and BKVΔagno.mediating the phosphorylation. Presence of Gö6976 prior to stimula-
tion with TPA or vanadate did also reduce phosphorylation of Ser-11
(compare lane 6 to 4 in both panels in Fig. 3C) but less efﬁcient than
Gö6983 inhibitor (compare lane 6 to 5). This argues against involve-
ment of PKD in mediating phosphorylation of agnoprotein at Ser-11.sfected in 12 well dishes with 800 ng DNA from BKV wt, BKVagnoS11A, BKVagnoS11D
protein expression was assayed by immunoblot with the indicated antibodies. The
ted by an arrow. The results are representative for four independent experiments.
of the viral protein was related to actin loading. The relative level of wildtype viral
this (shown in the left panel). (B) The media of Vero cells transfected with DNA from
UV-EC-C cells were ﬁxed 5 days after infection, and immunostained with indicated
dependent experiments. (C) Percentage LT-ag positive cells in (B) were counted in 4–6
in %-LT-ag positive cells between the different BKV variants inclusive wildtype was
Fig. 6. Mutation of Ser-11 reduces the transrepressive effect of agnoprotein. (A) Vero
cells were co-transfected in 6 well dishes with 2 µg empty expression vector pRcCMV,
pRcCMV-agno, pRcCMV-agnoS11A or pRcCMV-agnoS11D, respectively, and 1 µg
luciferase reporter plasmid. The expression of the luciferase gene is under control of
the late BKV (Dunlop) promoter. The luciferase activity in cell extracts was determined
the day after the transfection. The activity in extracts of cells transfected with the empty
pRcCMV expression vector was arbitrary set as 100% and the activities in the other
extracts were related to this value. The results represent the average of three parallels±
SD and the ﬁgure is representative for three independent experiments. Expression of
wildtype and mutant forms of agnoprotein was veriﬁed by western blot of cell lysates
and the loading was controlled by ERK2 antibodies (lower panel). (B) Vero cells
were transfected in 12 well dishes with 800 ng DNA from BKV wt, BKVagnoS11A or
BKVagnoS11D. Total RNAwas extracted 40 h.p.t, and reverse transcribed into cDNA. PCR
was performed with speciﬁc primers against VP1 or the housekeeping gene APRT. The
PCR products were analyzed on an agarose gel in presence of ethidium bromide.
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vanadate-induced phospho-Ser-11 levels, emphasizing that PKD did
notmediate agnoprotein phosphorylation by these stimuli (results not
shown). In conclusion, the stimuli-induced activation of PKC and/or
PKD in the presence or absence of inhibitors indicates that PKC,
but not PKD, can be involved in the phosphorylation of agnoprotein at
Ser-11 in vivo.
Finally, we wanted to check whether PKC is involved in phos-
phorylation of agnoprotein during BKV propagation. We transfected
Vero cells with the complete BKV Dunlop genome, and late in the ﬁrst
round of viral life cycle (2 days post transfection), the cells were
exposed to vehicle (DMSO), or to the inhibitors Gö6983 or GF109203X.
The latter compound inhibits the PKC α, β, γ, ε, η, θ and ζ isoforms.
One hour after the addition of inhibitor, the cells were harvested and
the phospho-Ser-11 levels of agnoprotein were monitored. First of all,
our result shows that agnoprotein was phosphorylated at Ser-11 late
in the viral life cycle in BKV-transfected Vero cells (Fig. 3D, lane 1,
upper panel). Moreover, the presence of PKC inhibitor Gö6983 as
well as GF109203X clearly reduced the phosphorylation of agnopro-
tein at Ser-11. These results underscore that PKC is involved in
mediating phosphorylation of agnoprotein at Ser-11 at this particular
time point during viral life cycle (Fig. 3D, upper panel). The presence
of comparable levels of agnoprotein in all samples was veriﬁed by
immunoblotting with antibodies against agnoprotein (Fig. 3D, lower
panel).
In conclusion, our ﬁndings clearly demonstrate that PKC, but
neither PKA nor PKD, can mediate phosphorylation of BKV agnopro-
tein at Ser-11 in vivo.
Agno-Ser-11 phosphorylation ﬂuctuates during BKV infection cycle
The phosphorylation of SV40 LT-ag at residue Thr-124 is the sole
post-translational modiﬁcation required for initiation of replication
(Kim et al., 2002 and references therein). The ability of regulating
the phosphorylation of this residue is critical for viral propagation, as
mutationof T124 in SV40 LT-ag or T125 in JCV LT-ag to alanine results in
a replication-defective virus (Schneider and Fanning 1988; Swenson
and Frisque, 1995). This clearly reveals that the ability of regulating
the phosphorylation state of a protein is highly important. The
phosphorylation pattern of a protein may vary in time-dependent
manner depending on the activity of cellular signal transduction
pathways, which again can be inﬂuenced by the state of viral life cycle.
Therefore, we wondered whether phosphorylation of agnoprotein at
Ser-11 in BKV-transfected- or infected cells is constitutive or ﬂuctuat-
ing. Thereto, Vero were transfected with BKV Dunlop DNA. We also
infected the human cell line HUV-EC-C, which is highly permissive for
BKV (Rinaldo et al., 2005). The cells were harvested after 24 h, and
then every hour from 43 and 50 h post transfection (h.p.t) or post
infection (h.p.i). The cell lysate was used in an immunoblot with the
phospho-Ser-11 speciﬁc antibodies (Fig. 4A, upper panel). The ex-
pression of agnoprotein was determined by the use of antibodies
against agnoprotein (Fig. 4A, middle panel), and loading was veriﬁed
by use of anti-CREB antibodies (Fig. 4A, lower panel). As can be seen in
Fig. 4A, middle lane, agnoprotein is expressed at all time points except
24 h.p.t/h.p.i, while phosphorylation of agnoprotein at Ser- 11 ﬂuc-
tuates in both cell lines (Fig. 4A, upper panel). Similar ﬂuctuation was
seen in both transfected Vero cells and infected HUV-EC-C from 33 to
57 h.p.t/h.p.i (results not shown).
The Vero and/or HUV-EC-C cells used above was seeded out one
day prior to transfection and/or infection, but were not synchronized
further. However, after transfection or infection the early gene
products of BK virus will enforce the cells into the S-phase (Moens
et al., 2007a,b), which results in a population where the majority of
cells is synchronized with the virus in a similar state of the viral life
cycle. In order to test this assumption, we wanted to evaluate whether
we were able to see ﬂuctuation in phosphorylation of an endogenousprotein in a time-dependent manner. CREB is a transcription factor
which is regulated by phosphorylation of Ser-133 (Johannessen et al.,
2004), and several kinases, including PKC (Xie and Rothstein, 1995),
may be involved in phosphorylating this residue. The membrane used
in Fig. 4A was stripped and evaluated with phospho-Ser-133 speciﬁc
antibodies. The ratio phospho-CREB versus CREB was determined and
is presented graphically in Fig. 4B. The result reveal that also the
phosphorylation pattern of an endogenous protein ﬂuctuates, con-
ﬁrming that most of the cells are relatively synchronized.
Mutation of Ser-11 inﬂuences viral propagation
Oscillations in the phosphorylation level of agnoprotein at serine
11 in both Vero and HUV-EC-C suggest a regulatory role of this post-
translational modiﬁcation during the viral propagation. To evaluate
the functional consequence of phosphorylation of agnoprotein on BKV
propagation, we employed BKV Dunlop strain encoding wildtype
agnoprotein, hereafter referred to as BKVwildtype, to create mutants
in which serine 11 was mutated to the non-phosphorylable alanine
(BKVagnoS11A) or to a phosphorylation mimicking aspartate (BKVag-
noS11D). We also generated an agno-deﬁcient BKV Dunlop strain
(BKVΔagno) by substituting the start codon with a non-sense codon,
and included this agnoprotein-deﬁcient strain in the experiments.
This control allowed us to compare the effect of mutations affecting
phosphorylation of agnoprotein versus the lack of agnoprotein expres-
sion on the viral replication.
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efﬁciency among BKV and BKV mutants were similar, as compared by
counting cells immunostained with antibodies against LT-ag, related
to DRAQ5 stained cells (data not shown). The amount of viral proteins
2 d.p.t. was determined by immunoblot with antibodies against VP1,
LT-ag, and agnoprotein. To ensure equal loading, we also monitored
the levels of actin in each sample. The strength of the protein bands
was evaluated by densitometry, and correlated to loading. The
wildtype level of viral protein was arbitrary set as 1, and the values
for the mutants were related according to this. The result showing the
viral gene expression is presented graphically beside the western blot
in Fig. 5A. The BKVΔagno had slightly increased level of LT-ag 2 d.p.t,
while BKVagnoS11A and BKVagnoS11D were comparable with
BKVwildtype (top band in Fig. 5A and results not shown). An
unspeciﬁc band, also visible in non-BKV-transfected cell migrated
just bellow LT-ag and was present in all samples. The amount of VP1
seemed to be comparable for BKV and BKVagnoS11A in all four parallel
experiments (Fig. 5A, and results not shown). In contrast, BKVag-
noS11D-transfected cells showed clearly reduced level of VP1, while
BKVΔagno clearly had increased VP1 level compared to the other BKV
variants in four independent experiments (Fig. 5A and results not
shown). The level of agnoprotein also varied among BKV and BKV
mutants. BKVagnoS11A expressed more agnoprotein than BKVwild-
type (after correction for actin), while the level was robustly reduced
in BKVagnoS11D-transfected cells (Fig. 5A and results not shown). As
expected, the BKVΔagno variant did not express the agnoprotein. The
pattern of viral gene expression was similar 4 and 8 d.p.t (results not
shown). These results indicate that BKV mutants have changed viral
gene expression compared to wildtype.
In order to compare the amountof released infectious viral particles
produced by the cells transfected with wildtype or mutant BKV
genomes, media was harvested 4 d.p.t. To ensure that the S11 muta-
tions or the non-sense mutation in Δagno were still present in the
genomes of the virus particles shed from the transfected Vero cells,
PCR ampliﬁcation and subsequent sequencing of the BKV DNA se-
quences present in the collected media was performed. The sequen-
cing results conﬁrmed that the introducedmutationswere still present
(data not shown). The collected media was then inoculated on HUV-
EC-C cells. Counting the number of BKV-positive HUV-EC-C cells willFig. 7. Agnoprotein localization in the cell. Confocal microscopy of Vero cells transfected w
immunostained with antibodies. (A) The LT-ag staining of a BKV-transfected cell (B) Agnopr
seen in (B) (D) Stack overlay labeled with agnoprotein (green), LT-ag (red) and DRAQ5 (bluethenprovide an estimate of the numbers of infectious particles present
in the media of BKV DNA-transfected cells (Dugan et al., 2007). The
HUV-EC-C cells, which were infected with media obtained from cells
containing replicating wildtype or mutant BKV genome, were DRAQ5
stained and immunoassayed with antibodies against LT-ag and
agnoprotein 5 d.p.i. (Fig. 5B). The number of infectious particles
present in the media from cells transfected with the individual BKV
variants was evaluated by counting the number of LT-positive cells
among DRAQ5 stained cells and is presented graphically in Fig. 5C.
While approximately 35% of the HUV-EC-C cells were infected by
media containing BKVwildtype, the number was 25% for media
containing BKVagnoS11A (Figs. 5B and C). The media obtained from
cells transfected with BKVagnoS11D and BKVΔagno contained a
similar number of infectious virions (around 15%), which was sig-
niﬁcantly less than the amount of infectious particles present in the
media of Vero cells transfected with BKVwildtype or BKVagnoS11A
DNA (Figs. 5B and C). These results indicate that mutations in the
phospho-acceptor site for PKC in agnoprotein affect viral propagation.
Moreover, this study shows that BKV lacking agnoprotein is infectious,
although with reduced property compared to BKVwildtype. Finally,
viral gene expression of BKV- or BKV mutant-infected HUV-EC-C cells
was evaluated by immunoblot using antibodies against LT-ag, VP1 and
agnoprotein. The results demonstrated that viral gene expression in
mutant-infected cells was changed compared to cell infected with
BKVwildtype in this cell line, too (results not shown).
In summary, our results noticeably demonstrate that BKV with
mutation in phospho-acceptor site Ser-11 hampers viral propagation
and results in changes in late viral gene expression compared to
wildtype.
Inﬂuence of Ser-11 phosphorylation on expression of viral proteins
We found that BKVΔagno had increased level of VP1 compared to
BKVwildtype, indicating that expression of agnoprotein reduced the
level of VP1 in vivo during BKVwildtype infection (compare BKVwild-
type with BKVΔagno in Fig. 5A). Moreover, the BKVagnoS11D had
reduced level of VP1 and agnoprotein, while BKVagnoS11A showed an
increased level of agnoprotein compared to BKVwildtype (compare
agnoprotein and VP1 levels for BKVwildtype-, and BKVagnoS11A-,ith 200 ng wt BKV DNA in 8 well Chamber slides. The cells were ﬁxated 2 d.p.t. and
otein-staining of a BKV-transfected cell (C) Enlarged section of the agnoprotein staining
).
Fig. 8. Mutation of Ser-11 inﬂuences the stability of agnoprotein. (A)Vero cells were
transfected with pRcCMV-agno, pRcCMV-agnoS11A or pRcCMV-agnoS11D. Cyclohex-
imide (100 µg/ml) was added and the cells were harvested 0, 2, 4, 6, 8 and 12 h after the
addition of protein synthesis inhibitor. An immunoblot was performed using antibodies
against agnoprotein (upper lane). To verify equal loading and blotting of the samples,
the membrane was stripped and re-incubated with anti-ERK2 antibodies (lower panel).
The results are representative for three independent experiments. (B) The relative levels
of wt agnoprotein and mutant protein were determined by densitometric scanning of
the signals obtained after immunoblotting. The strength of the signal obtained for the
protein level assays before the addition of cycloheximide (t=0) was arbitrary set as
100%.
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that agnoprotein and mutations that interfere with bona ﬁde
phosphorylation of the agnoprotein inﬂuence on late viral gene
expression. The gene expression is the sum of transcription, post-
transcriptional, translational and post-translational process (see
Discussion). We decided to evaluate the effect of agnoprotein and its
variants with a mutation in the phospho-Ser-11 site on the activity of
the late Dunlop promoter in order to test the effect on transcription.
Thereto, Vero cells were co-transfected with an expression plasmid
encoding wildtype agnoprotein, agnoproteinS11A or agnoproteinS11D
and a reporter plasmid with the luciferase gene driven by the late
promoter of BKV Dunlop. The presence of wildtype agnoprotein
repressed transactivation of the late BKV promoter by approximately
50%, while only a slight repression was monitored with agnopro-
teinS11A (Fig. 6A), suggesting that mutation into non-phosphorylable
alanine almost abolishes the repressive effect of agnoprotein. If so, one
might assume that a phospho-mimicking mutant agnoproteinS11D
should restore the transrepressive effect but surprisingly agnopro-
teinS11D showed similar transrepressive effect as agnoproteinS11A.
The expression level of agnoprotein in the cell lysates used for
luciferase measurements was then checked by immunoblotting with
antibodies speciﬁc for agnoprotein and the loading was controlled by
antibodies against ERK2 (Fig. 6A upper right corner). The result
revealed that the expression of agnoS11D clearly was reduced
compared to wt and agnoproteinS11A, which may explain the lack
of inﬂuence on the reporter. As a second experimental strategy, we
next wanted to evaluate whether the VP1 transcript levels varied
among the BKV variants. Total RNA was therefore harvested 40 h post
transfection and a semi-quantitative RT PCR was performed to
determine the mRNA levels of VP1. BKVagnoS11A-transfected cells
display increased VP1 transcript levels compared towildtype, which is
in agreement with the reporter assay shown in Fig. 6A. Similarly, the
BKVagnoS11D-transfected cells shows slightly increased VP1 mRNA
level compared to wildtype, but clearly less than BKVagnoS11A-
transfected cells, again in agreement with the reporter assays. Also
BKVΔagno-transfected cells shows clearly increased level of VP1
transcript, conﬁrming the transrepressive effect of agnoprotein seen
in Fig. 6A. This may also suggest that the increase of VP1 protein levels
seen for BKVΔagno in Fig. 5A indeed could be a consequence of
inhibitory function of agnoprotein at viral late gene transcription.
Phosphorylation may affect the intrinsic repression potential of
agnoprotein. Alternatively or in addition, phosphorylation may affect
the subcellular localization of agnoprotein and hence its ability to
inﬂuence promoter activity. Indeed, agnoprotein resides mainly in the
cytoplasm, but the agnoprotein of JCV and SV40 has also been found in
the nucleus (Khalili et al., 2005). Okada et al. (2001) reported that
phosphorylation of JCV agnoprotein altered its localization from
perinuclear region into the nucleus. Therefore, we wanted to evaluate
whether the differences in transrepressive property of wt and
mutated agnoprotein could be explained by phoshorylation-depen-
dent subcellular redistribution of the agnoprotein. Thereto, Vero cells
were transfected with BKV, BKVagnoS11A or BKVagnoS11D. Two days
post transfection, the cells were ﬁxated and immunostained with
antibodies against agnoprotein and LT-ag, while the nucleus was
stained with DRAQ5. At least 50 cells of each variant were examined
by confocal microscopy, where the nucleus was divided into several
sections. As seen in Fig. 7, a small fraction of BKV agnoprotein can
be detected in the nucleus. This was seen in approximately 10% of
the cells examined. The amount of cells containing agnoprotein in
nucleus did not differ signiﬁcantly among BKV, BKVagnoS11A and
BKVagnoS11D (results not shown). Therefore, we believe that the
differences in the transrepressive effect of agnoprotein versus
agnoproteinS11A on BKV late promoter (Figs. 6A and B) is not due to
phosphorylation-dependent changes in subcellular localization, but
rather originates from phosphorylation-triggered differences in the
intrinsic repression function of the protein.Mutation of Ser-11 inﬂuences the stability of BKV agnoprotein
The stability of several proteins has been shown to be regulated by
phosphorylation (Whitmarsh and Davis, 2000). This prompted us to
test whether the variations seen in the amount of agnoprotein in Vero
cells transfected with BKVwildtype compared to BKVagnoS11A and
BKVagnoS11D at day 2 (Fig. 5A) and in the lysates used in the luciferase
assays (Fig. 6A) could be due to differences in the phosphorylation-
regulated stability of the protein. Thereto, we transfected Vero cells
with expression plasmids for agnoprotein or agnoprotein mutated in
Ser-11 residue. The protein synthesis in the cells was inhibited by the
addition of cycloheximide and the level of agnoprotein was evaluated
by immunoblot with antibodies against agnoprotein at 0, 2, 4, 6, 8 and
12 h after the administering of cycloheximide. As depicted in Fig. 8, the
level of agnoproteinS11D was clearly reduced after 6 h, while the level
of wt agnoprotein was only slightly decreased at this time point. The
S11Amutation seemed to stabilize the agnoprotein because no obvious
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incubation with cycloheximide. In conclusion, phospho-mimicking
mutations trigger agnoprotein destabilization, while the non-phos-
phorylable alanine seems to increase the stability of agnoprotein. This
might partly explain the changed level of agnoprotein in the BKV- or
BKV mutant-transfected cells in Fig. 5A.
Discussion
In this studywe show that BKV agnoprotein can be phosphorylated
at Ser-11 by PKA, PKC and PKD, while the two latter enzymes also can
phosphorylate Ser-7 and Thr-21 in vitro. Moreover, we demonstrate
that PKC can be involved in Ser-11 phosphorylation of BKV
agnoprotein in vivo. The phosphorylation pattern of serine 11 of BKV
agnoprotein ﬂuctuates during viral propagation, suggesting an
important regulatory role. Indeed, our study reveals that mutation
of Ser-11 into alanine or aspartate results in disturbed propagation
with reduced production of infectious viral particle. Moreover, the
BKV variants with mutations in the phospho-acceptor site Ser-11 of
agnoprotein show a changed late gene expression compared to the
wildtype in the two tested cell lines. The reduced transcriptional
repression activity of the agnoproteinS11A and agnoproteinS11D
mutants on the BKV promoter is partly due to reduced intrinsic
repression potentials of the mutants compared to wildtype agnopro-
tein and to changed stability of agnoprotein variants.
The agnoproteins of BKV, JCV and SV40 are phospho-proteins
(Khalili et al., 2005). One study has suggested the involvement of PKA
in phosphorylation-mediated regulation of JCV agnoprotein (Okada
et al., 2001). In another study, PKC was added to cell lysate, containing
phosphatase-treated JCV agnoprotein, JCV agnoproteinT21A, JCV
agnoproteinS7A/S11/A or JCV agnoproteinS7A/S11A/T21A. The result
indicated that all three sites in JCV agnoprotein could be phosphory-
lated by PKC (Sariyer et al., 2006). In our study, we have found that
while PKA, PKC and PKD all can phosphorylate BKV agnoprotein in
vitro, only PKC seems to be involved in phosphorylation of BKV
agnoprotein Ser-11 in vivo as evaluated in cell culture system in the
presence of stimuli, inhibitors, or a constitutive active kinase variant.
Moreover, we also found that inhibition of the PKC pathway resulted
in reduced phosphorylation of agnoprotein at Ser-11 during viral
propagation 48 h post transfection. This clearly shows that PKC indeed
is able to phosphorylate BKV agnoprotein at Ser-11 in vivo during viral
infection. However, the viral life cycle occurs within a living cell,
where the different signaling pathways, involving numerous protein
kinases, may continuously be switched on and off depending on
environmental- and virus induced-stimuli. This may be reﬂected by
the ﬂuctuation of the Ser-11 during viral propagation (Fig. 4A). So even
though PKC can mediate in vivo phosphorylation at agnoprotein Ser-
11 at 48 h.p.t., other kinase(s) may be involved at other time points
during viral life cycle. Moreover, the activity and/or presence of
phosphatases may inﬂuence the phosphorylation of agnoprotein.
Indeed, for JC virus it was recently shown st-ag is involved in the
dephosphorylation of agnoprotein (Sariyer et al., 2008). In our study,
we also found that the phospho-acceptor sites Ser-7 and Thr-21 in BKV
agnoprotein may be phosphorylated by PKC and PKD in vitro.
However, it remains to be established whether PKC and/or PKD are
involved in the phosphorylation of these sites in vivo.
Comparisons of protein levels in Vero cells transfectedwith BKV- or
BKV mutants showed that BKVagnoS11A, BKVagnoS11D and
BKVΔagno had a changed viral late gene expression compared to the
wildtype (Fig. 5A). Gene expression is the sum of several processes and
includes among others: transactivation of the promoter, regulation of
RNA transcripts, translation efﬁciency, and stability of the protein
which all will be discussed regarding our result in the following.
Several studies in JCV have suggested that agnoprotein may be
involved in viral gene transcription. In one study, JCV Mad1 or JCV
Mad1Δagno was used to transfect the susceptible neuroblastomacell line IMR-32. The viral gene transcription of LT-ag, VP1 and agno-
protein were evaluated by RT PCR, and the authors conclude that the
absence of agnoprotein had a negative inﬂuence on viral transcription
(Okada et al., 2001). Here we found that agnoprotein with serine-11
replaced by alanine has reduced transrepressive effect on the late viral
promoter (Fig. 6). The agnoproteinS11D did not inﬂuence the late
transcription in Vero cells which may be due to its rapid degrada-
tion (Fig. 6A upper right corner and Fig. 8). Our results suggest that
phosphorylation of agnoprotein may inﬂuence the intrinsic repres-
sive property of the protein. The exact mechanism for agnoprotein-
mediated repression is not known, but as we found BKV agnopro-
tein in nucleus of 10% of the cells examined (Fig. 7), it may involve
phosphorylation-regulated interaction with nuclear proteins. Indeed,
studies with reporter constructs revealed that JCV agnoprotein can
interact with LT-ag and the cellular transcription factor YB-1, and
suppress JCV LT-ag-mediated transactivation of late reporter and YB-
1-mediated transactivation of both early and late reporter in the
human cell line U-87MG (Safak and Khalili, 2001; Safak et al., 2001;
Safak et al., 2002). Our preliminary results suggest that BKV LT-ag
and agnoprotein can interact in vivo (results not shown), however,
whether this interaction is regulated by phosphorylation aswell as the
biological consequence of this association remains to be investigated.
The level of VP1 varies among BKV-transfected cells, and the
highest level is observed in cells transfected with BKVΔagno (Fig. 5A).
Agnoprotein and VP1 are both assumed to be on the 16S transcript
(Cole and Conzen, 2001) and the ratio VP1 versus agnoprotein in Vero
cells transfected with BKV or BKV variants is not constant (Fig. 5A).
This argues against transactivation as the only regulatory mechanism
for the changed viral gene expression caused by the mutations in
agnoprotein. The change in viral gene expression as seen in Fig. 5A
might also be due to distinct abilities of agnoprotein variants to
inﬂuence the RNA levels. For SV40, an early study revealed that cells
infected with agnoprotein-deﬁcient mutants possessed increased
transcript levels of early mRNA and of the late 16S as well as the 19S
transcripts compared to wildtype infected cells. The rate of transcrip-
tion did not differ among wildtype and the agnoprotein-lacking
mutants, indicating that the observed increase in amount of
transcripts was due to some kind of post-transcriptional regulation
(Resnick and Shenk, 1986). BKV also produces 16S and 19S transcript
(Manaker et al., 1979; Moens et al., 1994), but whether BKV agno-
protein in a phosphorylation-regulated manner inﬂuences the mRNA
of late genes remains to be established. Therefore, we cannot rule out
that the increased VP1 protein levels in BKVΔagno and of agnoprotein
in BKVagnoS11A (Fig. 5A) result from changes at the post-transcrip-
tional level in addition to reduced transrepressive effect in the case of
agnoproteinS11A (Fig. 6A and B).
Polyomavirus transcripts are polycistronic, which is uncommon in
eukaryotic cell. Translation of mRNA usually starts with ribosomes
that enter at the 5′ end of the transcript, and then scan the mRNA for
the start codon. The efﬁciency of initiation of translation at this start
codon depends on its sequence context and the distance to 5′ end
(Kozak, 2007). Indeed, the efﬁciency of translational initiation of
agnoprotein at AUG has been shown to depend upon the distance to
the 5′ end (Sedman et al., 1990). Agnoprotein may thus be translated
with various degree of efﬁciency depending on the length of the
untranslated 5′ end of the transcript. In both 16S and 19S mRNAs, the
agnoprotein start codon precedes VP1, and VP2 and VP3 AUGs,
respectively (Dabrowski and Alwine, 1988). The presence of another
start codonmay affect translation from the downstream start codon as
was shown for SV40 late mRNAs, where mutation of the start codon of
SV40 agnoprotein resulted in increased VP1 expression (Grass and
Manley, 1987; Perez et al., 1987). In our study, we also observed
increased VP1 productionwith BKVΔagno, in which the start codon of
agnogene was mutated into TTG. This suggests that improved acces-
sibility of the VP1 start codon by the ribosomes may result in aug-
mented VP1 production.
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Sariyer et al. (2006) compared the expression of agnoprotein versus
agnoprotein T21A, S7A/S11A and S7A/S11A/T21A during viral propaga-
tion. They found that the JCV agnoprotein with mutations in the
phospho-acceptor sites was expressed to a higher level than wildtype
during the infection cycle. The increase of mutant agnoprotein
expression was, however, not due to elevated turnover rates (Sariyer
et al., 2006). We compared the stability of BKV agnoprotein versus BKV
agnoproteinS11A or BKV agnoproteinS11D and found that the latter
is less stable than wildtype, while agnoproteinS11A is more stable
(Fig. 8). This may partly explain the changes in mutant agnoprotein
levels compared to the wildtype protein observed in BKV-transfected
cells (Fig. 5A). It is also tempting to speculate that the mutation in
agnoprotein inﬂuences the VP1 stability, thereby causing the variable
VP1 levels seen among the different BKV variants in Fig. 5A. Studies
in SV40 have shown that agnoprotein may be involved in localization of
VP1, suggesting an interaction between the two viral proteins (Carswell
and Alwine, 1986). Moreover, one study revealed that missense
mutations in the VP1 gene of SV40 can compensate for defects caused
by deletions in the viral agnogene (Barkan et al., 1987), conﬁrming
putative interaction between the two viral proteins. Another early study
in SV40 demonstrated that the rate of expression of VP1 protein is
similar between wt SV40 and agnoprotein-deﬁcient SV40. However,
under long-term labeling conditionwhere labeled VP1 was representa-
tive for steady state VP1 level, the authors consistently observed 50%
reduction in VP1 accumulation inmutant versuswildtype infected cells.
The authors suggest that VP1 is less stable in absence of agnoprotein
(Resnick and Shenk,1986). Moreover, in another early study second-site
revertants were isolated of a partially defective VP1 mutant of simian
virus 40. The suppressing mutation in each of these pseudorevertants
was mapped to the viral agnogene. Of six independently isolated
pseudorevertants, all had amissensemutation in serine at position 7,11
or 17 in the agnoprotein by a hydrophobic amino acid. Their results
suggest that the agnoprotein interacts in a speciﬁc waywith VP1 during
the late stages of viral development and in the discussion the authors
speculated that agnoprotein and VP1 interaction may be regulated by
phosphorylation (Margolskee and Nathans, 1983). However, despite the
high amino acid identity between SV40 and BKV agnoprotein (67%)
(Moens et al., 2007a,b), an interaction between BKV agnoprotein and
VP1 and a possible involvement of protein phosphorylation remains to
be established.
Our BKVagnoS11A, BKVagnoS11D and BKVΔagnomutants still sus-
tained the viral infection cycle, even though at a lower the efﬁciency
compared to BKVwildtype. This seems in contrast with JCV where the
agnomutants T21A, S7A/S11A, and S7A/S11A/T21A were unable to
produce infectious virions, because these mutations interfered with
genomic encapsulation (Sariyer et al., 2006). However, we have not
investigated the viral replication efﬁciency of the corresponding BKV
mutants. Phosphorylation of the conserved phospho-acceptor sites in
BKV and JCV agnoproteinmay have different effects on the functions of
the proteins. Furthermore, BKV and JCV display distinct cell tropism
and hence agnoprotein function and regulation of these two viruses
may be cell-speciﬁc and explain the differences in viral propagation
between phospho-acceptor agnoprotein mutants of JCV and BKV.
Our results suggest that reduced propagation of the BKV mutants
compared to wildtype is partially due to disturbed viral gene
expression. Nuclear egress of JCV viral particles was shown to require
interaction of agnoprotein with HP1α (Okada et al., 2005). Whether
BKV agnoprotein interacts with HP1α and whether this interaction is
regulated by phosphorylation remains unknown, but the 18 ﬁrst
amino acids of JCV agnoprotein, which are absolutely necessary for the
association with HP1α (Okada et al., 2005), are conserved in BKV
agnoprotein (Moens et al., 2007a,b). Moreover, phosphorylation of
histone H1 by CDK regulates its binding to HP1α (Hale et al., 2006),
and it is tempting to speculate in a similar regulation of agnoprotein–
HP1α interaction.In summary, we have shown that BKV agnoprotein can be phos-
phorylated at Ser-11 by PKC in vivo. The phosphorylation pattern at
this site oscillates during viral infection cycle and mutations of this
residue reduced viral propagation. At least two mechanisms seem to
contribute to perturbed propagation of the agnoprotein serine-11
mutants: altered intrinsic transrepression function as well as stability
of the protein. Our results suggest that targeting PKC pathway by




12-O-tetradecanoylphorbol-13-acetate (TPA), sodium orthovana-
date, epidermal growth factor (EGF) and forskolin (fsk) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Thrombin was obtained from
Amersham Biosciences. Foetal Bovine Serum (FBS) and cell culture
medium were obtained from Invitrogen (Carlsbad, CA, USA). CDP-star
and MagicMark western standard were from Applied Biosystems (CA,
USA) and Invitrogen Life Technologies (Oslo, Norway), respectively.
Antibodies against agnoprotein were described previously (Rinaldo,
Traavik et al., 1998). Phospho-Ser-11 speciﬁc antibodies were ordered
from Eurogentec, which prepared afﬁnity-puriﬁed antibodies from
serum of rabbits immunized with KLH-conjugated CLSRQApSVKVGT.
CREB and phospho-CREB Ser-133 antibodies were obtained from Cell
Signaling Technology Inc. (Beverly, MA, USA), while the antibodies for
ERK2 and actin were from Santa Cruz and Sigma-Aldrich, respectively.
SV40LT-agAB-2was fromCalbiochem,while antibodies for BKVVP1has
been described previously (Grinde et al., 2007). Gö 6976 and Gö 6983
were from Calbiochem (CA, USA), while GF109203X was from Alexis.
Alkaline phosphatase conjugated anti-rabbit antibody was purchased
from DAKO (Denmark). Activated PKD1 was from Upstate (Medprobe,
Oslo, Norway), while the catalytic Cα subunit of PKA and PKC (P0329)
were purchased from Sigma-Aldrich.
Cell lines
HEK293 (ATCC CRL-1573), Vero (ATCC CCL81) and HUV-EC-C (ATCC
CRL1730)were all purchased fromAmericanTypeCulture Collection and
were maintained according to the instructions by the manufacturer.
The stimulus pervanadate was freshly prepared for each experiment
according to (Gordon, 1991).
Plasmid constructs and mutant viruses
The empty expression vector pEFneo and the plasmids containing
the coding sequences for PKCα A/C, PKCδ A/C and PKCɛ A/C were a kind
gift from Dr. G. Baier (Von Essem et al., 2006). PKCζA119E was kindly
provided by Dr. T. Johansen (Perander et al., 2001), while pSR and the
plasmid pSR Cα, containing the catalytic Cα subunit from PKA, were a
kind gift from Dr. T. Jahnsen and Dr. K. Taskén (Foss et al., 1994). The
plasmids pcDNA3.1 andpGEX-4T-1were purchased from Invitrogen and
GE Healthcare, respectively. Constitutive active PKD (744/748E/E
mutant) and pRcCMV-agno have been described previously (Johannes-
sen et al., 2007a,b; Rinaldo et al., 1998). pRcCMV-agnoS11A and
pRcCMV-agnoS11D were created by site-directed mutagenesis by use
of pRcCMV-agno as a template. An XbaI sitewas created into pGEX-4T-1
generating pGEX-4T-1X by site-directed mutagenesis. Then, EcoRI and
XbaIwereused to excise theagnocoding sequences frompRcCMV-agno,
and the agno-fragment was cloned into the pGEX-4T-1X vector, result-
ing in pGEX-4T-1X-agno. pGEX-4T-1X-agno was used as a template in




plasmid p34-2 was obtained from ATTC (cat. no. 45025). To minimize
the risk for unwanted mutation during PCR-based site-directed
108 M. Johannessen et al. / Virology 379 (2008) 97–109mutagenesis, we created a plasmid with part of BKV genome encom-
passing the region/sequences encoding agnoprotein. The approximately
500 bp NdeI–PciI fragment of digested p34-2 was ligated into NdeI–PciI
digested pUC18, creating the plasmid agno-pUC18. Agno-pUC18 was
used for site-directed mutagenesis in order to convert agno-Ser-11 into
alanine (agnoS11A-pUC18) or aspartic acid (agnoS11D-pUC18) and to
convert the start codon intoTTG resulting inplasmidnamed agno-puc18
Δagno. To be able to reintroduce the mutated 500 bp NdeI and PciI
fragment into the BKV genome, we needed to go through an inter-
mediate step with a larger part of the BKV genome in a modiﬁed pUC18
vector (pUC18m). pUC18m, lacked NdeI and PciI sites and contained
unique BglII and MfeI sites, and was created by NdeI and PciI digestion
of pUC18 followedby ligationof a synthesizedoligo createdbyannealing
5′-tac gcc atg cat tgt tag atc tag agt cca att gca cct taa gat gc-3′ and 5′-cat
ggc atc tta agg tgc aat tgg act cta gat cta aca atg cat ggc g-3′. p34-2 was
thereafter digested with BglII and MfeI and the approximately 1700 bp
BglII–MfeI BKV fragment was ligated into pUC18m resulting in the
plasmid named modiﬁed pUC18-BKV. Into this modiﬁed pUC18-BKV
were the agnoS11A-puc18, agnoS11D-puc18 and Δagno-puc18 inserted
by digestion with NdeI and PciI and ligated into NdeI and PciI digested
modiﬁed pUC18-BKV. In the last step, the modiﬁed pUC18-BKV with
mutated insertions, was digested with SacI, and the resulting 500 bp
DNA fragment containingpart of agnogenewasused to replace the same
fragment in partial digested p34-2 backbone, according to the cassette
model described previously (Johnsen et al., 1995). pGL3-basic was
purchased from Promega. pGL-TCR-EL was created by amplifying the
transcription control region (TCR) from p34-2 by use of NCCR.F (5′-cta
agc ttt tgc aaa aat tgc aaa aga ata gg-3′) and NCCR.R (5′-gta agc ttg gcc ttt
gtc cag ttt aac tg-3) primers. The PCR product was digested with HindIII
and ligated into pGL3-basic. The orientation of TCR was determined by
sequencing. Puriﬁed BKV Dunlop was a kind gift from Dr. C.H. Rinaldo
(Rinaldo et al., 1998).
Site-directed mutagenesis
All PCR-based site-directed mutagenesis were performed using
Stratagene Quickchange according to the instructions of the manu-
facturer (Stratagene, La Jolla, CA, USA). The complementary primer
sets for the generation of mutant plasmids were as follows (only one
strand is shown): XbaI-primer: 5′-gga att ccc ggg tcg tct aga gcg gcc
gca tc-3′; S7A: 5′-ctg cgc cag ctg gca cga caa gct tca g-3′; S11A: 5′-ca
cga caa gct gca gtg aaa gtt ggt aaa acc-3′; S11D: 5′-ca cga caa gct gac gtc
aaa gtt ggt aaa acc-3′; T21A: 5′-cct gga ctg gag caa aaa aaa gag ctc aga
gg-3′; S62A: 5′-gct gta aaa gac gct gta aaa gac tcc-3′; Δagno: 5′-ctg gac
aaa ggc ctt ggt tct gcg cca gct g-3′. All mutations were veriﬁed by
sequencing.
Sequencing
Cycle sequencing was performed using the Big Dye sequencing kit
version 3.1 (Perkin-Elmer-Tropix). Sequencing reactions were ana-
lyzed on an ABI377 Prism Sequencer (Perkin-Elmer).
In vitro kinase assay
In vitro kinase assay was performed as outlined before (Van Lint
et al., 1998). GST fusion proteins were puriﬁed from Escherichia coli
BL21 extracts using glutathione–agarose beads, and the agnoprotein
moiety was removed from the GST-beads by use of thrombin accord-
ing to the instructions of the manufacturer.
Transient transfection
Transfection studies with expression plasmids in HEK293 and Vero
cells were done using Lipofectamine 2000 (Invitrogen) according to
the instructions of the manufacturer. Luciferase assays were as pre-
viously described (Johannessen et al., 2004). Before transfection of the
BKV genome, the genomewas BamHI digested out of the vector and re-
ligated with T4-ligase giving a pool with re-ligated BKV genome and
re-ligated pBR322 vector.Infections
HUV-EC-C cells were treated with virus containing media for 2 h at
37 °C, followed by addition of fresh media. Four days later, the cells
were either PFA ﬁxated for immunoﬂuorescence analyses, or cell
extracts were harvested and used for immunoblot analyses.
Immunoﬂuorescence analyses
Cells were rinsed twice with phosphate-buffered saline (PBS) and
ﬁxed for 10 min with 4% formaldehyde. Next, the cells were washed
twice with PBS and then permeabilized for 10 min with 100%
methanol (−20°) for 10 min, and washed twice with cold PBS prior
to blocking for 30 min with 3% goat serum at room temperature. Viral
proteins were recognized by agno-serum (1:600) and SV40 AB-2 LT-ag
1:100), and stained with secondary antibodies Alexa Fluor 568 (red)
to detect LT-ag and Alexa Fluor 488 (green) to detect agnoprotein.
The cells were then washed with PBS and examined using confocal
laser-scanning Zeiss LSM 510 META and Leica SP5 microscopes. Cell
nuclei were visualized by DRAQ5 staining (Biostatus Ltd., Leicester-
shire, UK).
Immunoblot analysis
Immunoblot analyses were performed on in vitro phosphorylated
proteins or extracts derived from cells as described previously
(Johannessen et al., 2007a,b). The densitometric analysis of western
blot was accomplished usingMulti Gauge Ver3.0 (Fujiﬁlm Life Science,
Japan). The measurements were corrected for background signal and
normalized to loading control.
RNA isolation and reverse transcriptase polymerase chain reaction (RT PCR)
cDNA was made and subjected to PCR. The primers for APRT and
the PCR conditions have been previously described (Johannessen et al.,
2004). To amplify VP1 cDNA, the following primers were used: 5′-
CTTTGCTGTAGGTGGAGAACC C-3′ (forward) and 5′-CTCCTGTGAAA-
GTCCCAAAATAC-3′ (reverse). The PCR cycling conditions were 20
times 94 °C for 30 s, 65 °C for 30 s, and 72°C for 2 min s. The VP1
primers were kindly provided by Dr. Christine H Rinaldo, University
Hospital of North Norway, Tromsø.
Statistical analysis
Student's t-test and differences with p-valuesb0.05 were con-
sidered as signiﬁcant.
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